Antimalarial Therapy for Lupus Erythematosus: An Apparent Advantage of Quinacrine
- 1 January 1981
- journal article
- Published by Wiley in International Journal of Dermatology
- Vol. 20 (1) , 57-60
- https://doi.org/10.1111/j.1365-4362.1981.tb05295.x
Abstract
A retrospective study of 26 quinacrine-treated lupus erythematosus patients failed to show evidence of drug-induced ocular changes. Although quinacrine commonly produces minor side effects, such as yellow discoloration of the skin, and may rarely produce very serious side effects, such as aplastic anemia, it appears to produce much less oculotoxicity than does chloroquine.Keywords
This publication has 16 references indexed in Scilit:
- Ocular Toxicity of Antimalarial DrugsAmerican Journal of Ophthalmology, 1968
- Ocular Changes Induced by Long-Term Hydroxychloroquine (Plaquenil) TherapyAmerican Journal of Ophthalmology, 1967
- CHLOROQUINE RETINOPATHY WITH RECOVERY IN EARLY STAGESThe Lancet, 1964
- ChloroquineArchives of Dermatology, 1963
- Toxic Effect of Chloroquine on Porphyria HepaticaArchives of Dermatology, 1962
- TREATMENT OF LUPUS ERYTHEMATOSUS WITH CHLOROQUINE..British Journal of Dermatology, 1957
- QUINACRINE HYDROCHLORIDE (ATABRINE) IN THE TREATMENT OF LUPUS ERYTHEMATOSUSArchives of Dermatology, 1953
- CHLOROQUINE DIPHOSPHATE IN TREATMENT OF DISCOID LUPUS ERYTHEMATOSUSJAMA, 1953
- Clinical Notes, Suggestions and New InstrumentsJAMA, 1946
- EDEMA OF CORNEA PRECIPITATED BY QUINACRINE (ATABRINE)Archives of Ophthalmology (1950), 1946